Synaffix BV

Based in the Netherlands, Synaffix BV develops innovative biopharmaceutical technologies, focusing on antibody-drug conjugates (ADCs) that enhance cancer treatment efficacy. Founded in 2010 in Oss, Netherlands, Synaffix BV is focused on advancing biopharmaceutical technologies, specifically in the field of ADCs. Under the leadership of CEO Peter Van de Sande, the company has completed 2 deals, with the most recent on June 1, 2023, when it underwent a TRADE SALE to Lonza Group Ltd. for EUR 100 million, raising a total of EUR 100 million.

The company does not have any known subsidiaries and has not undergone significant business pivots since its inception. Synaffix specializes in providing advanced biopharmaceutical technologies with a focus on antibody-drug conjugates (ADCs) and bispecific antibodies. Its proprietary platform technology, centered around the antibody glycan, allows partner companies to develop customized, state-of-the-art ADCs that target cancer therapeutics more effectively. The company’s technology is designed for rapid deployment, enabling biopharmaceutical organizations to integrate these capabilities into their own pipelines.

Synaffix's client base includes prominent pharmaceutical companies engaged in oncology, particularly in North America, Europe, and Asia. The ADCs developed using Synaffix's technology aim to address critical challenges in targeted cancer therapies, enhancing the efficacy and safety profiles of these treatments for end-users, which include healthcare providers and patients undergoing cancer treatment. Synaffix operates under a focused technology out-licensing business model, generating revenue primarily through licensing agreements and partnerships with pharmaceutical companies. The company enters into contracts with clients for the use of its ADC technology, facilitating a transition from preclinical development to clinical trials and potential commercialization.

Revenue transactions are structured as B2B partnerships, where pharmaceutical firms license Synaffix’s technology to augment their oncology pipelines. These agreements often involve milestone payments and royalties contingent upon the successful advancement of therapeutic candidates through various clinical phases. Synaffix’s notable collaborations include licensing arrangements with Boehringer Ingelheim and Mitsubishi Tanabe Pharma, contributing to a robust framework for revenue generation within the biopharmaceutical sector. The company's EBITDA for the most recent year, 2023, stands at EUR 18,002,329.

With the acquisition by Lonza Group Ltd. occurring on June 1, 2023, the firm aims to leverage this partnership to enhance its bioconjugates offerings. Looking ahead, Synaffix is expected to focus on developing new ADC products and expanding into additional markets, particularly targeting North America and Asia. The recent funding will provide resources essential for these initiatives, facilitating advancements in product development and market reach.